Varici DX CEO details commercial traction, multi-omics pipeline, and path to cash flow break-even following recent fundraise
Summary
Varici DX CEO Sarah Barrington discusses the company's RNA-based diagnostics for kidney transplant rejection, noting adoption in 36 US centers and a compressed sales cycle. She outlines a strategy to reach cash flow break-even by generating 7,000 annual orders, supported by an 8.75 million pound fundraise. The company also highlights a multi-omics 'Clear Lab' incubator service and a new genetic predisposition test called Transcriptics as value drivers. Barrington emphasizes that the primary focus remains on core diagnostic growth while the multi-omics segment serves as a potential self-funding expansion.
Episode sections
- 0:00 – 1:01
Sponsor Reads
Ads for Homes by Avi rent-to-own program and North Star Ford vehicle financing.
- 1:01 – 1:58
Podcast Introduction and Company Overview
Host Paul Hiller introduces CEO Sarah Barrington of Varici DX, a medical diagnostics firm focused on the kidney transplant market, following an 8.75 million pound fundraise.
- 1:58 – 4:51
Technology Differentiation and Clinical Utility
Barrington explains that Varici DX uses RNA signatures and AI to provide precise, early detection of transplant rejection, addressing the lack of specificity in older injury markers.
- 4:51 – 7:30
Commercialization Status and Market Penetration
The company is in 36 of approximately 180 US transplant centers, covering over 23% of the patient population, with sales cycles compressing from six months to three months.
- 7:30 – 11:39
Testing Frequency and Recurring Revenue Model
Clinicians use the test an average of 12 times per patient per year for surveillance and clinical indications, creating a recurring revenue stream.
- 11:39 – 17:18
Market Segmentation and Competitive Landscape
Barrington divides the market into thirds: incumbents, Varici's target 'tricky' patients, and emerging demand from CMS IOTA initiatives.
- 17:18 – 22:50
Fundraise Use of Funds and Path to Break-Even
The 8.75 million pound raise funds commercial expansion to reach cash flow break-even by the end of next year, targeting 7,000 annual orders.
- 22:50 – 30:24
Product Portfolio Updates and Pipeline
Updates include the licensed test Clariva (now Petra) with Thermo Fisher, a new fibrosis test, a genetic predisposition test called Transcriptics, and CRO services.
- 30:24 – 31:21
Multi-omics testing capabilities and partnerships
The company operates a regulated 'Clear Lab' for multi-omic testing, acting as an incubator for researchers requiring sophisticated wet lab and bioinformatics infrastructure.
- 31:21 – 33:18
Operational requirements and incubator model
Multi-omics requires highly skilled personnel for wet lab precision and AI algorithms, serving researchers who cannot justify independent infrastructure costs.
- 33:18 – 34:18
Revenue magnitude and strategic focus
Revenue from the multi-omics segment is described as 'multiple millions' but is dependent on headcount allocation, with the main business remaining the primary focus.
- 34:18 – 35:55
Closing remarks and near-term outlook
The company aims for absolute growth and cash flow break-even, thanking shareholders for confidence in the recent Private Equity Placement to unlock hidden value.
Claims worth verifying
Varici DX raised 8.75 million pounds in a fundraise last month.
Unidentified speaker ·1:32
How to verify: Check Varici DX's regulatory filings or press releases for the specific fundraise announcement and amount.
There are approximately 180 transplant centers in the US.
Unidentified speaker ·5:47
How to verify: Verify with American Society of Transplantation (AST) or UNOS (United Network for Organ Sharing) data on active transplant centers.
Varici DX is currently in 36 transplant centers, covering over 23% of the US transplant patient population.
Unidentified speaker ·5:44
How to verify: Cross-reference Varici DX's commercial reports with UNOS transplant volume data to calculate patient coverage percentage.
The weighted average number of tests per patient is 12 times over an 18-month period.
Unidentified speaker ·8:18
How to verify: Request clinical usage data or published case studies from Varici DX detailing test frequency per patient cohort.
Sales cycles have compressed from six months to three months.
Unidentified speaker ·9:45
How to verify: Analyze Varici DX's internal sales metrics or customer acquisition timelines reported in future earnings releases.
The Total Addressable Market (TAM) is $900 million, based on 28,000 transplants, 12 tests, and $2,650 per test.
Unidentified speaker ·11:56
How to verify: Verify 28,000 annual transplant volume with UNOS data and confirm test pricing with hospital procurement records or competitor pricing.
Delayed graft function (DGF) rates have increased from 26% to between 30% and 60% due to the use of riskier organs.
Unidentified speaker ·14:13
How to verify: Review medical literature or transplant registry data (e.g., OPTN/UNOS) for trends in DGF rates and organ quality metrics.
Varici DX aims to reach cash flow break-even by the end of next year with 7,000 annual orders.
Unidentified speaker ·20:56
How to verify: Monitor Varici DX's quarterly financial reports for revenue recognition and operating cash flow metrics.
Thermo Fisher licensed the Clariva test and paid 5 million in upfront milestones.
Unidentified speaker ·23:48
How to verify: Check Thermo Fisher Scientific's SEC filings (10-K or 10-Q) for licensing agreements and milestone payments.
The new fibrosis test is launching as a Research Use Only (RUO) product.
Unidentified speaker ·27:15
How to verify: Check Varici DX product announcements or FDA/CE marking status for the specific fibrosis test.
The company operates a 'Clear Lab' that is compliant with regulatory audits for multi-omic testing.
Unidentified speaker ·30:24
How to verify: Check Verici DX's latest annual report or investor presentation for details on laboratory certifications and regulatory compliance status.
The multi-omics segment involves both diagnostic and drug development applications, including RNA signatures and proteomics.
Unidentified speaker ·31:53
How to verify: Review Verici DX's press releases or partnership announcements for specific collaborations in RNA signatures or proteomics.
The multi-omics segment is expected to generate 'multiple millions' in turnover, depending on resource allocation.
Unidentified speaker ·33:39
How to verify: Analyze Verici DX's financial filings and management commentary for revenue breakdowns or forward-looking statements regarding the multi-omics division.
The company recently completed a Private Equity Placement (PEP) funded by shareholders.
Unidentified speaker ·34:28
How to verify: Search for Verici DX's regulatory filings (e.g., SEDAR in Canada) for announcements regarding equity issuances or private placements around the time of the podcast.
The company's primary near-term goal is reaching cash flow break-even.
Unidentified speaker ·34:45
How to verify: Review Verici DX's financial statements for cash flow from operations and management's guidance on profitability timelines.
Do your own research
- Verify the 8.75 million pound fundraise details and current cash position in recent SEC filings or press releases.
- Check the specific CMS IOTA initiative requirements and their impact on transplant center procurement decisions.
- Review clinical validation data for the RNA signature technology compared to incumbent biopsy methods.
- Analyze the competitive landscape of kidney transplant biomarkers, including incumbents and other emerging technologies.
- Confirm the regulatory status and reimbursement codes for the Clariva/Petra test with Thermo Fisher.
- Investigate the financial performance and order volume of the lead territory cited as exceeding 350 orders per quarter.
- Assess the regulatory compliance and capacity of the 'Clear Lab' for multi-omic testing services.
- Review the terms and dilution impact of the recent Private Equity Placement (PEP).
Full transcriptexpand
- 0:00
- Unidentified speaker: Move in.
- 0:01
- Unidentified speaker: Earn purchase credits.
- 0:02
- Unidentified speaker: Make your move.
- 0:03
- Unidentified speaker: Discover Homes by Avi's rent-to-own program currently available on Sweets and stovered on 17th in the heart of Michigan's vibrant walkable area.
- 0:12
- Unidentified speaker: After one year, you'll earn purchase credits with every rent payment.
- 0:15
- Unidentified speaker: When you're ready to make your move, those credits will be applied to the closing costs of your new home with Homes by AVI.
- 0:21
- Unidentified speaker: Three simple steps make it easier to go from renting to owning your own place.
- 0:26
- Unidentified speaker: To learn more, visit homesbyavy.com slash rent to own.
- 0:30
- Unidentified speaker: Marty here at North Star Ford, Electra's.
- 0:33
- Unidentified speaker: Can you believe BC?
- 0:34
- Unidentified speaker: They don't like the NDP much.
- 0:36
- Unidentified speaker: Not sure what happened, but at North Star, we love NDP.
- 0:39
- Unidentified speaker: Who doesn't love no down payment?
- 0:41
- Unidentified speaker: All November, all 2026s come with NDP and NP.
- 0:44
- Unidentified speaker: No payments till February 27th.
- 0:46
- Unidentified speaker: If Sisters don't like the NDP, sure we'll take your down payment to lower your payment, but we will not cash your check till February 27th.
- 0:54
- Unidentified speaker: Love NDP or hate it, it's a big tent at North Star.
- 0:57
- Unidentified speaker: Call 239-3715 or visit North Star4Calrie.ca today.
- 1:01
- Unidentified speaker: The Vox Markets Podcast.
- 1:03
- Unidentified speaker: Nothing in this podcast is intended as investment advice, and the people in this podcast may hold positions in the stocks they talk about.
- 1:09
- Unidentified speaker: Do not buy anything based solely on a tip or recommendation.
- 1:12
- Unidentified speaker: Please do your own research.
- 1:14
- Unidentified speaker: Welcome back everyone to Vox Markets.
- 1:16
- Unidentified speaker: My name is Paul Hiller, and I'm delighted again to be able to speak to CEO Sarah Barrington of Varici DX, a next generation medical diagnostics firm focusing on the global kidney transplant market.
- 1:27
- Unidentified speaker: So uh big welcome, Sarah.
- 1:29
- Unidentified speaker: Just great to be back again, Paul.
- 1:31
- Unidentified speaker: You know that.
- 1:32
- Unidentified speaker: Yeah, well, uh big congrats on last month's uh very successful uh 8.75 million pound um fundraise, but we've already sort of run through the details on that and where the funds are going to be used.
- 1:44
- Unidentified speaker: I don't suppose you could just quickly remind investors where exactly Verici plays in the global kidney transplant market and more importantly, what its real sort of like unique um proposition is differentiation.
- 1:58
- Unidentified speaker: Yeah, I mean uh I I think most companies come along and say we've got the next generation technology and everybody does a big eye roll, right?
- 2:06
- Unidentified speaker: Um, but for uh but for once it actually has a real um real substance to this one.
- 2:12
- Unidentified speaker: What we found was um a market that had had biomarkers in a technology which was later and an injury marker, uh, and of course that's better than uh nothing or a biopsy, uh, and it certainly uh was very helpful to the transplant clinician.
- 2:31
- Unidentified speaker: Um, but our founder uh recognized that it was probably not precise enough, it was not specific enough, uh, and she was very interested in developing something that would be used earlier uh and with uh with more precision right down to the patient level, uh, as she said with immunosuppression, which is the drug um uh therapy.
- 2:54
- Unidentified speaker: She said one size does not fit all, and that's how we're doing it.
- 2:56
- Unidentified speaker: So we're looking for that next generation.
- 2:59
- Unidentified speaker: So we uh use RNA signatures, um, which is RNA is all the messaging of the body, so it's very proactive material, and then we uh ask very specific clinical questions, that's and the answer are these signatures.
- 3:13
- Unidentified speaker: Um, you know, we use AI in that development and in the management of the signature, uh, and I won't bore everybody with uh with the real uh nerdy stuff, although I love it.
- 3:23
- Unidentified speaker: Um, but essentially it offered clinicians that was something very unique.
- 3:28
- Unidentified speaker: Uh, it was early, um, both in time, so it didn't get confounded by the injury of the surgery itself.
- 3:34
- Unidentified speaker: It was early in the biologically, so now it's proactive.
- 3:39
- Unidentified speaker: You know, clinicians are being able to say, okay, I think damage is about to happen.
- 3:44
- Unidentified speaker: Um, so I've got those very early stages.
- 3:46
- Unidentified speaker: And of course, the the golden rule of diagnostics is uh, you know, earlier is better.
- 3:52
- Unidentified speaker: And then lastly, uh, you know, we're seeing now in real world evidence clinicians using it to um to mark the the progress of a patient when they're altering the level of drug.
- 4:05
- Unidentified speaker: So immunosuppression take the entire immune system away.
- 4:09
- Unidentified speaker: We know how scary that was from COVID.
- 4:12
- Unidentified speaker: Um, and so they're balancing between rejection on one hand, infection on the other, cancer, toxicity issues.
- 4:20
- Unidentified speaker: So it's kind of like a seesaw.
- 4:21
- Unidentified speaker: They're looking for that balance.
- 4:23
- Unidentified speaker: They didn't have the precise tools to be able to do it.
- 4:26
- Unidentified speaker: And uh now we see clinicians using Trutivia in that way to get the balance on the Cesaw uh to down to the individual patient level.
- 4:36
- Unidentified speaker: So completely um uh you know unique competitive positioning there.
- 4:41
- Unidentified speaker: Uh, and we're thrilled to say that uh I can do it without the red face test.
- 4:45
- Unidentified speaker: Uh uh, we are the next generation technology.
- 4:48
- Unidentified speaker: Fantastic.
- 4:49
- Unidentified speaker: Uh and how's the commercialisation going?
- 4:51
- Unidentified speaker: Because I didn't notice obviously in the first half you had a 52% increase in your top line for that two tivia test um going forward and sort of like where you where you are in terms of uh coverage of transparent centers and sort of anything you can give us on run rate and how you see things moving forward on that commercialization strategy?
- 5:09
- Unidentified speaker: Yeah, well, everybody knows uh that we've been kind of operating a little bit with uh what we might call under-resourced.
- 5:16
- Unidentified speaker: And um, you know, so I you know, I make this joke that we you've done our growth to date with uh two men and a dog, or two people and a dog, as it really was, um, and the dog is asleep on the couch.
- 5:29
- Unidentified speaker: But uh, you know, uh effectively uh what we're seeing is that uh with limited resource, uh a take up in the market, which I think um shows the confidence uh and the interest in this new technology.
- 5:44
- Unidentified speaker: So we're actually in 36 centers.
- 5:47
- Unidentified speaker: If you think there are about 180 uh transplant centers in the US, and and we we talk about being global, but we're really talking about the US at the moment, that's our first push.
- 5:57
- Unidentified speaker: Um so there are 180 addressable um centres in the US.
- 6:02
- Unidentified speaker: Uh so 36, there's roughly about 20% of those.
- 6:05
- Unidentified speaker: So um when we look down to the base patients, uh how many transplant surgeries are they doing, that's uh that's a that's over 23% of the patient population.
- 6:16
- Unidentified speaker: Now I'd love to say that Tutyvia is being used by everyone on every one of those patients, um, but we've got a little way to go.
- 6:24
- Unidentified speaker: The important thing is that with very limited resources uh in the first half of this year, we were able to get into those centres and be able to at least work our way through those patient populations.
- 6:36
- Unidentified speaker: So um that was very encouraging.
- 6:39
- Unidentified speaker: Um, then obviously, you know, I would like to remind everybody that's not just about uh revenue in this business, it's also about being paid.
- 6:47
- Unidentified speaker: So that Medicare coverage determination was incredibly important to us.
- 6:52
- Unidentified speaker: That was about 18 months ago now, and we saw the uptick from uh centres once uh, you know, from the credibility of that what was a year's review uh on our data.
- 7:04
- Unidentified speaker: Uh, we gave them all the source data.
- 7:06
- Unidentified speaker: It's you know, nothing very transparent process.
- 7:09
- Unidentified speaker: Um, and then also to to know that their patients are not going to be, you know, left holding the bill.
- 7:16
- Unidentified speaker: So, you know, that's an important milestone for us uh about 18 months ago, and we've been seeing that steady adoption ever since into those centers.
- 7:25
- Unidentified speaker: So very important um growth for us uh and those milestones.
- 7:30
- Unidentified speaker: Yeah.
- 7:30
- Unidentified speaker: And then the last time we spoke, you mentioned each particular transplant patient, but there's potentially twelve up to 12 sort of testing occurrences that could potentially occur.
- 7:40
- Unidentified speaker: How are you are you seeing anything at the coal face whereby the clinicians are using Tutyvia more than once on a particular patient?
- 7:47
- Unidentified speaker: Are you seeing that one on particularly on the the uh transplant centers that you started earlier on?
- 7:53
- Unidentified speaker: Yeah, absolutely.
- 7:54
- Unidentified speaker: I mean, if you look at the protocols, uh that sort of weighted average of 12 times is over the um uh uh apologies everyone for this uh sunshine uh through my blinds.
- 8:05
- Unidentified speaker: Um but uh I uh you know what we saw was when we looked at all the protocols across the centers that over the 18-month period that they're really focused on this uh this part of the care pathway.
- 8:18
- Unidentified speaker: Uh we saw a weighted average of about 12 times.
- 8:21
- Unidentified speaker: Um obviously for us, as you look at the um, you know, that's a combination between what we call surveillance, okay, a monitoring over time, it's very time-based, right?
- 8:31
- Unidentified speaker: I don't think anything's going on, but I want to check in with my patient, and what we call uh clinical indication or focus.
- 8:38
- Unidentified speaker: So I think something's going on, and roughly that's about half the patient.
- 8:41
- Unidentified speaker: So I think something's going on.
- 8:42
- Unidentified speaker: I want to know what that is, and obviously that's earlier in the process as the uh patient is getting used to their own uh org, you know, new organ, the graft, um, and uh you know, can be very intensively.
- 8:56
- Unidentified speaker: And of course, when we saw the case studies where the clinicians are using it to titrate the immunosuppression level, you see it being uh the case studies being presented that it 2 TV is being used multiple time points.
- 9:08
- Unidentified speaker: You know, I'll use it until I get to that sweet spot, I'll use it to confirm that now I've had to raise that to get to my balance, that it's it's not rejecting, and so on and so forth.
- 9:18
- Unidentified speaker: So that kind of monitoring uh is very much uh the evidence that we see that that 12 times is is probably um you know a very robust number and obviously robust for us uh in terms of that recurring uh revenue.
- 9:34
- Unidentified speaker: Um we're also seeing that um we're taking seeing the sales cycle uh compress as well, uh, you know, something that it took us six months to do.
- 9:45
- Unidentified speaker: We're now seeing is happening in three months.
- 9:48
- Unidentified speaker: Uh we talk about the the pyramid of uh progression uh in our centers as we get uh to to be addressed by the patients, and we see them being using it kind of one off, uh, you know, as I try and work out how I'm gonna put this into my practice.
- 10:04
- Unidentified speaker: Then we see that recurring from how I'm gonna use it in that way for those patients, then we see it getting to other colleagues.
- 10:13
- Unidentified speaker: So we've got multiple clinicians in a center using it in that recurring manner, and then we go to the protocol.
- 10:19
- Unidentified speaker: Well, to get from I've started, I'm a new center down to that multiple clinician would take us six, nine months uh to you know, in the beginning.
- 10:28
- Unidentified speaker: We're now seeing that as uh you know more like three months, and in fact, uh one center literally within the month went from that to the multiple, uh, and then now our third uh largest ordering center.
- 10:42
- Unidentified speaker: So, you know, what I'm seeing is what you're looking for is that tipping point.
- 10:46
- Unidentified speaker: Where am I getting that trust equation uh from clinicians that first of all they're starting to trust it themselves?
- 10:55
- Unidentified speaker: They've looked at the literature, they've talked to their peers, um, and how we're seeing that peer-to-peer interaction.
- 11:03
- Unidentified speaker: Are they waiting for us a grand rounds when they come into the center and talk to the other clinicians, or are they now picking up the phone?
- 11:11
- Unidentified speaker: So I think for us, we're seeing that tipping point where we're seeing uh the compression of that sales cycle into that recurring revenue and then being able to be addressed by more and more patients in that centre.
- 11:25
- Unidentified speaker: So uh for us, it's a very exciting time.
- 11:29
- Unidentified speaker: Um, you know, I talk about growth being inevitable, it's a tipping point.
- 11:32
- Unidentified speaker: Nothing's inevitable in life, but you know, uh, you get my point that we're we're very excited about the stage we're at commercially.
- 11:39
- Unidentified speaker: Yeah.
- 11:39
- Unidentified speaker: And out to that sort of total sort of 900 million through a total addressable market, you know, times 12, 12 times testing, and then it'll hit 28,000, I think transplants and you get you know $2,300 per test or something like that.
- 11:53
- Unidentified speaker: You get to about $2,650, yeah.
- 11:56
- Unidentified speaker: Yeah, you get you get to that, you get to sort of like $900 uh million.
- 12:00
- Unidentified speaker: How much of that is white space in terms of sort of like there's nobody really looking after that, and how much is is a cumbers?
- 12:05
- Unidentified speaker: Because just as an example, let's just say, for instance, you know, I'm a complex, which I am, sort of like you know, kidney transplant patient, and the doctor's a bit concerned about what level of immunosuppressant they should give me in terms of whether I should, you know, if I'm gonna get an infection or alternatively whether it's gonna damage my kidney, etc.
- 12:23
- Unidentified speaker: It how how would how would you see that in terms of white space and sort of like incumbents?
- 12:28
- Unidentified speaker: Because that's really your that's your sweet spot, isn't it?
- 12:32
- Unidentified speaker: You know, when we looked incumbents in healthcare uh are incredibly powerful, it's hard to dislodge once you're in and familiar and you're in the processes, it's very hard to dislodge.
- 12:43
- Unidentified speaker: So we looked at that uh total addressable market, and what we realized was that we could divide it into thirds.
- 12:51
- Unidentified speaker: So a third of that market um is currently covered by the old technology, the the incumbents.
- 12:58
- Unidentified speaker: Um, and uh obviously they're they're very robustly within those hospital centers, you know.
- 13:05
- Unidentified speaker: They've got the easy button, they've got the logistics, they got the support, um, and that would be very hard to dislodge.
- 13:13
- Unidentified speaker: And then we looked at the uh other two-thirds.
- 13:17
- Unidentified speaker: Um, one third is what we call the really tricky patients where the old technology couldn't be used or wouldn't be used by the clinician.
- 13:26
- Unidentified speaker: So they've tried it out, they don't think it works.
- 13:29
- Unidentified speaker: And the reason for that is that it's highly nonspecific.
- 13:32
- Unidentified speaker: So it's an injury marker.
- 13:33
- Unidentified speaker: If you've got any kind of source of uh injury, it's gonna be throwing that off.
- 13:39
- Unidentified speaker: Um, so for example, in the very early days, there's a condition called uh DGF, delayed graph function.
- 13:46
- Unidentified speaker: It's when it's been on a cool box, it's very cold, it takes a while to warm up in the body.
- 13:51
- Unidentified speaker: Now, is it going to take?
- 13:52
- Unidentified speaker: Is it rejecting or is it just slow?
- 13:55
- Unidentified speaker: And they couldn't use a marker that was going to be confounded by the the injury of the surgery, right?
- 14:01
- Unidentified speaker: Um, so and and we're seeing rates now of DGF um went from 26% up to between 30 and 60 percent because they're taking on more risky organs.
- 14:13
- Unidentified speaker: So that was a problem, and then areas that where they have an infection, um it was also non-specific.
- 14:21
- Unidentified speaker: So it would say, I can tell you something's going on, but I can't tell you what.
- 14:25
- Unidentified speaker: So they couldn't do this balancing act.
- 14:27
- Unidentified speaker: Um, so you know, we saw many, and there are there are many others, multiple organs, for example.
- 14:33
- Unidentified speaker: Something's going wrong, can't tell you what.
- 14:36
- Unidentified speaker: Prior transplant, it's in there.
- 14:38
- Unidentified speaker: So the old ones giving you injury markers, can't distinguish between old and new.
- 14:42
- Unidentified speaker: So you've got all of these conditions.
- 14:44
- Unidentified speaker: Well, we we sort of did our calculations um and said you'd probably have some overlap.
- 14:49
- Unidentified speaker: So it's probably another third of the market where that need for the next generation of technology uh was apparent.
- 14:57
- Unidentified speaker: You've got something that is built up, they you know, all the systems are set up to take a test, but they can't use it in those subpopulations.
- 15:05
- Unidentified speaker: So you don't often have that opportunity uh to lean into not only an unmet need, but one that's already primed and pumped to go.
- 15:15
- Unidentified speaker: Uh, and I think that that was very significant for us, realizing that that was our entry point, what we call the low-hanging fruit, where you can go in and say, your primed and punked are ready to go to have a test, but you've got nothing in this area, we can offer you something.
- 15:29
- Unidentified speaker: So, you know, very interesting.
- 15:31
- Unidentified speaker: And then the other third of the market um was interesting to us, which was uh, you know, where we might, if you remember the old technology, you know, uh terminology from crossing the chasm, um, that you know, you would have the late adopters.
- 15:46
- Unidentified speaker: And uh boy, we saw a lot of centers say, well, I don't like this new technology very much.
- 15:52
- Unidentified speaker: I prefer my biopsy, it's about the same price, I get more information, and I don't like that it's fairly non you know, non-specific.
- 16:00
- Unidentified speaker: Um, but at the moment, there's a government initiative.
- 16:03
- Unidentified speaker: I think we gave an RS on it, which sort of backs this up.
- 16:06
- Unidentified speaker: But from from CMS, there was an initiative called IOTA, and it said we need to do more transplants.
- 16:12
- Unidentified speaker: To do that, you need to do more risky organs.
- 16:14
- Unidentified speaker: But by the way, we don't want you to sacrifice any of your quality measures.
- 16:18
- Unidentified speaker: So, you know, you've got more difficult patient and organ uh situations, and so it's forcing that sort of other third of the market to say, right, well, now I do need a biomarker in that area.
- 16:32
- Unidentified speaker: Um, and that's fair game between us and the incumbents.
- 16:35
- Unidentified speaker: We're all going after that space, but I'd like to think that you know, we offer something better uh for those clinicians that probably were a little skeptical about the lack of specificity before, and now we're looking for that, and of course, that that next level of information is something that we're giving.
- 16:51
- Unidentified speaker: So, to us, you know, you have one uh one-third of the market, prime and pumps, let's go.
- 16:58
- Unidentified speaker: Second one, which is kind of emerging as a trend, and that's uh then the third is with the incumbents, and you know, um, do we ever have to go head to head with them?
- 17:08
- Unidentified speaker: No, we are being more than happy to have two-thirds of them of that market.
- 17:12
- Unidentified speaker: No, I'm not surprised.
- 17:14
- Unidentified speaker: Okay, so just returning then to the the fundraise, the 8.75 million.
- 17:18
- Unidentified speaker: Where are you planning to deploy the funds and also to talk through sort of like how that gets you to sort of uh becoming self-financing?
- 17:27
- Unidentified speaker: Yeah, so first of all, I'd just like to acknowledge the shareholders that participated in that, and I'd like to say thank you very much for your vote of confidence.
- 17:35
- Unidentified speaker: Um, you know, I think what we were able to show was that we're at that tipping point.
- 17:41
- Unidentified speaker: Um, we've got a clear line of sights to cash flow break-even.
- 17:46
- Unidentified speaker: And at the moment, um, you know, we're we're all looking at the valuation of the company, reflecting the funding risk.
- 17:54
- Unidentified speaker: Um, you know, this constant need to keep coming back, doing small raises, you know, obviously gives a lot of insecurity to um to shareholders about the value of this company.
- 18:05
- Unidentified speaker: Remove that um uh that downwards pressure from a funding risk.
- 18:11
- Unidentified speaker: Um, and I think everybody said, okay, let's get back to a valuation based on business fundamentals, uh, which we can always chat about at great length, but it's interesting, it's significantly higher than when you've got the downward pressure of the funding risk.
- 18:26
- Unidentified speaker: So they looked at it and said, okay, do you have a credible um line of sight to break even?
- 18:31
- Unidentified speaker: And our growth curve uh would suggest that we do by the end of next year.
- 18:36
- Unidentified speaker: And so the idea was to raise enough uh with a little bit of wiggle room built in to get to that point.
- 18:45
- Unidentified speaker: Um, and so we were absolutely thrilled to have that vote of confidence to say you're at that point, let's put the funds in, let's get this company um back to that cash flow break-even, um, you know, within that timescale.
- 19:00
- Unidentified speaker: Uh, and obviously we need a few more resources to do that.
- 19:02
- Unidentified speaker: We're not going mad, by the way.
- 19:04
- Unidentified speaker: We have all the metrics around uh the resources we need.
- 19:07
- Unidentified speaker: I can tell you that if you think about the lead salespeople, we need about 12 to 15 to cover the whole country.
- 19:15
- Unidentified speaker: It's a 15 centre to one ratio uh at maturity.
- 19:20
- Unidentified speaker: Uh, we are just uh we've got four, we're bringing on another two.
- 19:24
- Unidentified speaker: Um, so you can see that we're balancing but what we need to fund out of equity funds beyond and then growth after that out of operational funds.
- 19:34
- Unidentified speaker: So we're making a little investment to get to that cash flow break-even so that we can move and grow out of our own operational funds uh after that point.
- 19:42
- Unidentified speaker: So, you know, uh that's essentially what we're doing when you look at the use of funds.
- 19:48
- Unidentified speaker: Uh we're putting it mostly into the commercial team.
- 19:51
- Unidentified speaker: There are a few other areas in terms of the value drivers of the company.
- 19:55
- Unidentified speaker: Uh, you know, we always look to see uh if we need to do um uh or or would like to do an exit at any point, what are the value drivers for any potential acquirer?
- 20:05
- Unidentified speaker: We have a certain number in our portfolio that we need to do, but really the main use of funds is in sales and marketing to get us to that cash flow break-even point off the back of two Tivia.
- 20:17
- Unidentified speaker: And when will that happen?
- 20:18
- Unidentified speaker: Is it sort of like 12 months' time or something like that?
- 20:21
- Unidentified speaker: Yeah, so uh, you know, obviously we're we're growing at a pace.
- 20:24
- Unidentified speaker: Uh the percentage is always fun, and you see a kind of cumulative quarter-on-quarter growth.
- 20:30
- Unidentified speaker: Uh, so we said, okay, what's uh, you know, without going mad on your investments, uh, what's uh and you can see how we're doing that with the sales team and and the that the need for having support beyond them.
- 20:43
- Unidentified speaker: Um then uh we we worked it out and said, okay, our break-even point is probably 7,000 uh orders, or and of course the revenue recognition is is getting paid on those that's resulted, but 7,000 in a year.
- 20:56
- Unidentified speaker: If you look at that on a quarter by quarter basis, that would break down to 1750 a quarter.
- 21:02
- Unidentified speaker: Uh the way that we cumulatively grow uh quarter on quarter, that gets us to uh around about the end of next year.
- 21:10
- Unidentified speaker: Um, and we said, okay, you know, it does again does that pass the red face test?
- 21:16
- Unidentified speaker: So we said, okay, let's look at our lead territory.
- 21:19
- Unidentified speaker: It's been uh serviced by by the company uh for at least a year longer than the other territory.
- 21:26
- Unidentified speaker: So let's say that that's our blueprint for where we want to go.
- 21:30
- Unidentified speaker: Um it's in excess of this, but uh say it's at 350 uh a quarter.
- 21:37
- Unidentified speaker: Uh if we bring bring on the other territories, uh we're going for six, we only need five of them to reach that level, and we're at that 1750.
- 21:46
- Unidentified speaker: So it has a kind of credibility to that growth as we reflect the investments that we're putting into each territory.
- 21:56
- Unidentified speaker: That sounds very uh positive because uh that means presumably then in 2028 you'll be doing turnover, must be over 16 million dollars per annum and be cash flow positive, I guess, is that's the that's the ethics.
- 22:10
- Unidentified speaker: That's the goal.
- 22:10
- Unidentified speaker: That's the goal of fantastic.
- 22:13
- Unidentified speaker: And I can tell you we've got a dedicated team.
- 22:16
- Unidentified speaker: Uh, you know, I'll give a shout-out to my team every single time.
- 22:19
- Unidentified speaker: Um, they're they've got a growth uh mentality.
- 22:23
- Unidentified speaker: Um, they've incredibly loyal to the company and to the cause.
- 22:27
- Unidentified speaker: Um, we saw that we had um people stay with us you know through through the last few rounds when it was all very insecure for the company.
- 22:35
- Unidentified speaker: Um, and I'd like to give a shout out to them because they have worked extraordinarily hard.
- 22:40
- Unidentified speaker: They're all doing a job and a half, and uh we're all very focused on getting to that point.
- 22:45
- Unidentified speaker: So you've got a team that's uh energized, excited, and ready to go.
- 22:49
- Unidentified speaker: Fantastic.
- 22:50
- Unidentified speaker: Uh I suppose you now could uh take us through just any quick updates on the other two tests you have the Proteasia and also the one we're doing with um Thermo Fisher.
- 22:59
- Unidentified speaker: Plus, obviously, you've made a couple of announcements in that sort of CRO area where you're doing sort of diagnostics for development of other drugs.
- 23:07
- Unidentified speaker: Yeah.
- 23:08
- Unidentified speaker: Yeah, I mean, I want to say obviously we're really focused on our lead products uh that we sell directly.
- 23:14
- Unidentified speaker: Um, but um you never want to be a one-hit wonder, right, in the music trade.
- 23:19
- Unidentified speaker: So uh we're the same in healthcare.
- 23:22
- Unidentified speaker: Uh so we always looked at this portfolio of offerings.
- 23:25
- Unidentified speaker: Um, you know, our first one was Clarava, which became Petra when it was licensed by Thermo Fisher.
- 23:31
- Unidentified speaker: Um, you know, they licensed it extremely early.
- 23:34
- Unidentified speaker: Uh, and I've always said that, you know, there's two parts of that value equation.
- 23:38
- Unidentified speaker: The first one was the upfront milestones, which was uh obviously not equity financing uh at the company when equity was extraordinarily expensive for us.
- 23:48
- Unidentified speaker: So incredibly important to get that um, you know, five million in the door uh to be able to progress the company.
- 23:56
- Unidentified speaker: So that was the real, you know, you got the upfront value.
- 24:00
- Unidentified speaker: And of course, the brand credibility.
- 24:01
- Unidentified speaker: Thermo came in, looked at uh the tests, and took it just straight out of the kind of the validation that that is very unusual for them.
- 24:09
- Unidentified speaker: Um and so I think we saw a lot of kind of bump in terms of the um the credibility of the company from that uh brand recognition.
- 24:18
- Unidentified speaker: And then you've kind of got the later because it then becomes a licensing deal where you're only getting a percentage of that sale, you've got to get the volume ramp up until uh so towards the back end.
- 24:28
- Unidentified speaker: So we said there'll always be this middle point where it's kind of like you know, not significant for the company.
- 24:34
- Unidentified speaker: Uh, we'll have the upfront benefit, we'll have the back um uh benefit.
- 24:39
- Unidentified speaker: Now to get sales in in uh in healthcare, we've seen it from our own experience with TuTivia, you've got to have a publication, and that came out uh June of this year.
- 24:50
- Unidentified speaker: Um, you know, it's novel technology, these things take longer to be accepted by the journals, to go through the peer reviews, um, to get the analysis, to get that credibility from the publication.
- 25:02
- Unidentified speaker: So it took us a little bit longer, um, but it got done in in June.
- 25:07
- Unidentified speaker: To that point, then the uh clinicians need to work out how they're going to use it.
- 25:12
- Unidentified speaker: It's novel.
- 25:13
- Unidentified speaker: Um, you look at for early adopting centers, those that will take it into their centres, they'll try it out, they then go and you know have this peer-to-peer um uh evidence.
- 25:24
- Unidentified speaker: And we're kind of working with Thermo in a co-marketing way, looking at these opportunities to be able to put them into centers that perhaps have used Two Tivia and are interested in, you know, what's next.
- 25:37
- Unidentified speaker: Um, so that will take time.
- 25:39
- Unidentified speaker: We're in that kind of lull at the moment.
- 25:41
- Unidentified speaker: So I uh David and I decide to take all the projections out.
- 25:45
- Unidentified speaker: Um, you know, people want to know that we're getting to break even without it.
- 25:49
- Unidentified speaker: So we've done that.
- 25:50
- Unidentified speaker: We're in that lull, and then later on we're looking for that hockey stick or the cross stick, as I call it, um, of uh that inflection point, and then it will start getting interesting to us.
- 26:00
- Unidentified speaker: So very much um, you know, where it's supposed to be at the moment, um, and we're kind of in that middle phase.
- 26:07
- Unidentified speaker: Um, so that's one that was the pre-transplant.
- 26:10
- Unidentified speaker: Obviously, tutivia is kind of the early rejection.
- 26:14
- Unidentified speaker: And then long-term outcomes, um, you know, um, we talk about it being the fibrosis test, uh, fast progression and fibrosis will uh lead to to graph uh failure.
- 26:27
- Unidentified speaker: So uh it's not just uh fibrosis, but let you know, let's not get too nerdy, although I'd love to, uh, in terms of what goes into those long-term outcomes.
- 26:37
- Unidentified speaker: Um, and that we we see a couple in a couple of ways.
- 26:41
- Unidentified speaker: First of all, clinically it is needed, uh, but there is no real solid so what.
- 26:48
- Unidentified speaker: Um, so yes, I can identify you, but what can I do about it?
- 26:52
- Unidentified speaker: And we've seen many of the fibrosis drugs um be put on the shelf.
- 26:56
- Unidentified speaker: Um, we think that that is because they are probably different mechanisms.
- 27:00
- Unidentified speaker: You know, patients can be very complex and and you will need to segment your patient population.
- 27:05
- Unidentified speaker: We think we're going to be useful in that.
- 27:07
- Unidentified speaker: And so we're launching that um uh I think towards the end of the year, uh around that time, anyway, as a research use only product where we can go to the drug development companies and say, okay, but this is where we think it's really useful.
- 27:22
- Unidentified speaker: We'll have a look at it clinically.
- 27:24
- Unidentified speaker: There are some things that they can do, but I don't think it's going to be really compelling in the clinical environment until we really have this in the research market.
- 27:33
- Unidentified speaker: So that's how we're positioning that that product.
- 27:36
- Unidentified speaker: And then did you see we've got a new product?
- 27:39
- Unidentified speaker: What was that one?
- 27:40
- Unidentified speaker: Called transcriptics.
- 27:42
- Unidentified speaker: So um, you know, we're all used to um uh the equivalent would be the bracogene mutation for breast cancer or ovarian cancer.
- 27:50
- Unidentified speaker: So, you know, that's where uh we these kind of tests have really uh gained uh the public's kind of imagination.
- 27:58
- Unidentified speaker: Um, and but in every area you kind of have that approach which is uh genetically, are you predisposed?
- 28:05
- Unidentified speaker: And there, you know, transplant patients have their own set.
- 28:09
- Unidentified speaker: Um we watched um uh uh clinicians in the absence of having nothing um look for something like that, and they took a competitors test that was in kidney disease, but it wasn't in transplant.
- 28:22
- Unidentified speaker: Um so might not be quite on point.
- 28:24
- Unidentified speaker: There's been a lot of discussion clinically about that, and we recognized that we had the opportunity out of our own uh data to be able to do a test like that.
- 28:35
- Unidentified speaker: So so we did.
- 28:36
- Unidentified speaker: Um, I I laughingly call it the no cost because we had it all, right?
- 28:41
- Unidentified speaker: A little bit of bioinformatics time, internal time, uh, but we were able to produce this and we'll be looking, you know, validated in transplants, the right uh panel, uh, and then that will come at the end of the year.
- 28:54
- Unidentified speaker: And the the real important thing for that, I mean, apart from it's a separate test, um, high margin, because it, you know, if you bundle it with with the other tests, uh the blood has already been sequenced, so you've got the data.
- 29:06
- Unidentified speaker: So, you know, it gives us a lot of opportunity.
- 29:09
- Unidentified speaker: So obviously you get the revenue from the test itself, uh, and obviously that adds to our corporate valuation.
- 29:15
- Unidentified speaker: Um, but to me, uh, if we bundle it with the other two tests, um, then obviously clinicians are, you know, get the the efficiencies from that, uh, which I think is really important.
- 29:29
- Unidentified speaker: Uh, but obviously we see it as an engine of growth for the for the other areas where where we think that bundling will be of of great interest.
- 29:37
- Unidentified speaker: So, you know, um I'm just excited that you know, some of the past investment that we've made in this company, and we've always said we we can leverage that.
- 29:48
- Unidentified speaker: Uh, we've just absolutely done that and given an example of that.
- 29:52
- Unidentified speaker: Uh, and I think it's going to be a real value driver of the company.
- 29:56
- Unidentified speaker: So that's kind of on the individual test level.
- 29:59
- Unidentified speaker: And then what we recognized, uh, you mentioned the CRO.
- 30:02
- Unidentified speaker: What does that mean?
- 30:03
- Unidentified speaker: Well, uh in healthcare, in research, in running a clinical trial, you you are looking for partners that can do the testing, the wet lab part of it, and the complexity of testing in the multi-omic space.
- 30:19
- Unidentified speaker: That's our technology with in transcriptomics and we're doing proteomics.
- 30:24
- Unidentified speaker: So we call it the multi-omic area, but all these new cutting-edge technologies, very few of them are done within what we call a regulated environment, our Clear Lab, CAP, etc.
- 30:36
- Unidentified speaker: We have all these sort of regulatory audits that are done and say that we comply to a different level.
- 30:42
- Unidentified speaker: So this specialty uh testing lab is kind of of interest.
- 30:45
- Unidentified speaker: So you see us, um, it's not a main focus, but we see quite a lot of inbound activity where people want to partner with us.
- 30:53
- Unidentified speaker: And we've made a few announcements that show that that's kind of a growing side of the business.
- 30:58
- Unidentified speaker: Obviously, uh, you know, uh, not our main focus uh where we're really behind the two tivia, but I think a recognition of some of the mega trends in the area in this healthcare space, which is looking to multi-omics development, and there's quite a lot that's happening in the research and therefore the trial environment, and and I think that that's a valuable uh string to our bow.
- 31:21
- Unidentified speaker: Yeah.
- 31:21
- Unidentified speaker: What sort of application areas would it be?
- 31:23
- Unidentified speaker: Is it is it gonna be sort of like new drugs for kidney transplants to basically rather than just the old immunosuppressants, or is it gonna be new drugs outside of kidney transplants into proteomics and to you know RNAs?
- 31:36
- Unidentified speaker: Both okay, right, fine.
- 31:38
- Unidentified speaker: Yeah.
- 31:38
- Unidentified speaker: You're gonna be you're gonna be busy then, aren't you?
- 31:41
- Unidentified speaker: And also um uh we do have a collaboration with with somebody who does RNA signatures but in a different disease groups.
- 31:53
- Unidentified speaker: Um so it's it's both diagnostic and drug development.
- 31:58
- Unidentified speaker: It's anyone that's really looking to be able to do um, you know and don't forget for us, multi-omics means you've got to have a wet lab, so you've got to have very sophisticated people in the labs that got that level of precision, and it uh that that's difficult in itself.
- 32:14
- Unidentified speaker: We we have very high, highly skilled people within the lab.
- 32:17
- Unidentified speaker: But then you have the bioinformatics team that put together the kind of data processing, what we call the algorithms.
- 32:23
- Unidentified speaker: This is where the AI part of come into it, the deep learning.
- 32:27
- Unidentified speaker: Uh, those algorithms need a bioinformatics capability.
- 32:30
- Unidentified speaker: So, so modern testing is not just in the lab, it's that wet lab plus your uh bioinformatics and then putting it together in a regulated environment.
- 32:40
- Unidentified speaker: Still not that common.
- 32:42
- Unidentified speaker: And so we do see a lot of interest in researchers or anybody that's trying to promote or incubate their testing um in that kind of environment, and obviously where the cost of setting up that that infrastructure uh is not warranted in the early days from the numbers.
- 33:00
- Unidentified speaker: So we're seeing a number of initiatives now where we're being a kind of incubator, um, and obviously that can roll out if they get the numbers, um, you know, but it's it is a very valuable part of the uh testing and the healthcare environment, particularly in these states.
- 33:18
- Unidentified speaker: Obviously, it's not in your forecast, but I don't want to put you on the spot here, um Sarah.
- 33:21
- Unidentified speaker: But in five years' time, can you just give us a feeling of how big would it be?
- 33:25
- Unidentified speaker: A million dollar turnover, would it be five million, ten million?
- 33:28
- Unidentified speaker: Where would you sort of like think it could get to just the magnitude?
- 33:33
- Unidentified speaker: It's a function of uh how how many resources, as in headcount we would put behind it.
- 33:39
- Unidentified speaker: Uh, but yes, it would be multiple millions.
- 33:42
- Unidentified speaker: It's it yeah, it it depends on how much focus, you know.
- 33:46
- Unidentified speaker: It's an interesting string to our boat.
- 33:48
- Unidentified speaker: I'm gonna reassure investors that we're really focused on our main business.
- 33:52
- Unidentified speaker: Yeah.
- 33:53
- Unidentified speaker: Uh, but as we think about, you know, total enterprise value, we do look at these value drivers.
- 33:58
- Unidentified speaker: Um, and so you know, if it takes off and it becomes self-funding, uh, then it'll have more resource and more push behind it, and then we can grow it.
- 34:07
- Unidentified speaker: But uh yeah, I'm not gonna be stuck to a number.
- 34:09
- Unidentified speaker: You can tell it's a very valuable part uh if you gr if you put the resources in.
- 34:13
- Unidentified speaker: Okay, you've got plenty of plenty of things to uh to leave us to pull there to uh to win.
- 34:18
- Unidentified speaker: Uh just and finally then just closing remarks for shareholders over the next sort of six to twelve months, what they should look out for.
- 34:25
- Unidentified speaker: Uh growth.
- 34:26
- Unidentified speaker: Absolute growth.
- 34:28
- Unidentified speaker: You know, we've uh we've now had uh the PEP put back in our step from the confidence from shareholders on giving us that kind of last round.
- 34:37
- Unidentified speaker: Um, so I want to thank the shareholders for that.
- 34:40
- Unidentified speaker: Uh it's been you know tough in the markets, um, but uh here we are.
- 34:45
- Unidentified speaker: Um and uh the team are very focused on growing the business and getting to cash flow break-even and uh looking forward to sort of unlocking uh what we think is the hidden value in this company from the business fundamentals.
- 34:58
- Unidentified speaker: Brilliant.
- 34:59
- Unidentified speaker: Okay, well, thanks again for your time and uh very much looking forward in touching base in a couple of months' time to see how things are progressing.
- 35:04
- Unidentified speaker: So uh well done, Sarah.
- 35:06
- Unidentified speaker: Thanks, Paul.
- 35:08
- Unidentified speaker: The Vox Markets Podcast.
- 35:10
- Unidentified speaker: Nothing in this podcast is intended as investment advice, and the people in this podcast may hold positions in the stocks they talk about.
- 35:16
- Unidentified speaker: Do not buy anything based solely on a tip or recommendation.
- 35:19
- Unidentified speaker: Please do your own research.
- 35:24
- Unidentified speaker: Forty and North Star Ford and I love separation.
- 35:27
- Unidentified speaker: Between long years, that is, and I love unification that Southern Alberta's only seven-day-a-week service department brings.
- 35:32
- Unidentified speaker: Alberta's made it clear we're better together.
- 35:34
- Unidentified speaker: Pipeline Talk has us optimistic about 2027.
- 35:37
- Unidentified speaker: Our Ford Credit Friends, combined with our lower margins, make it possible for us to offer 2027 Fords at 2026 pricing.
- 35:43
- Unidentified speaker: A 2027 for a 2026 price is not fake news because North Star pays you 500 if we get beaten.
- 35:49
- Unidentified speaker: Offer ends November 30th.
- 35:50
- Unidentified speaker: Call 239 0015 or visit North StarFordCalorie.ca today for details.
More from The Vox Markets Podcast
2536: Blackbird Takes Off With New CEO
Episode discussion: Blackbird CEO Sumit Rai outlines Elevate.io's pivot to the middle-market video editing sector and 18-month self-sufficiency goal
Speakers’ claims: Sumit Rai, CEO of Blackbird, discusses the strategic shift of the company toward Elevate.io, a video editing platform targeting the 'middle market' of corporate and educational users. He notes that the product has evolved from a fledgling division into the company's primary focus, aiming to capture growth driven by YouTube and corporate communications. Rai highlights that the company has reached 1,000 paying users but emphasizes the need to become self-sufficient within 12 to 18 months. The discussion contrasts Elevate.io with high-end Hollywood tools and low-end social media apps, positioning it for intuitive corporate adoption.
2535: 2 P's on a Pod: Which Turnarounds Can Deliver?
Episode discussion: Paul Scott and Paul Hill discuss UK small-cap turnarounds, valuation traps, and cybersecurity risks in trading platforms.
Speakers’ claims: Paul Scott and Paul Hill analyze various UK small-cap stocks, highlighting opportunities in Cavendish Financial, Volex, and Dialight while warning against balance sheet weaknesses in companies like Seeing Machines and Videndum. They debate the valuation of IG Group and Wise, with Scott favoring IG's turnaround potential and Hill noting its low multiple relative to Robinhood. The speakers also critique WH Smith's accounting quality and discuss the AI-related risks facing Ingenta and the cybersecurity sector.